Inventiva publishes lanifibranor trial results in Journal of Hepatology

Inventiva (IVA) announced the publication in Journal of Hepatology, a peer-reviewed scientific journal, of the results from the investigator-initiated clinical study led by Kenneth Cusi evaluating lanifibranor in patients with type 2 diabetes and Metabolic dysfunction-Associated Liver Disease. The clinical trial demonstrated improvement of hepatic, muscle and adipose tissue insulin resistance in patients with MASLD and T2D treated with lanifibranor. The proof-of-concept trial evaluating lanifibranor in 38 patients with MASLD and T2D achieved its primary efficacy endpoint. Patients that received treatment with lanifibranor achieved a 44% reduction in intrahepatic triglycerides measured using proton magnetic resonance spectroscopy, significantly outperforming the placebo group. The treatment with lanifibranor also resulted in a higher proportion of patients achieving over 30% liver triglyceride reduction and MASLD resolution. Secondary endpoints showed improvements in glycemic control, lipid profiles, hepatic insulin sensitivity, muscle glucose disposal, and adipose tissue function. Lanifibranor was well tolerated with no safety concerns reported. These findings are consistent with those reported in previous trials with lanifibranor and highlight lanifibranor’s potential for managing MASLD, T2D, and related metabolic conditions.